TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2647315
Drug: FAM therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAM therapy
Study: 563620
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ferrous sulfate (80 mg Fe++) and folic acid (350 microgram)
Study: 563620
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate (80 mg Fe++)
Study: 31349916
Drug: 42-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 42-day course of dexamethasone (0.5 mg/kg/day × 3 days followed by a slow taper, n=30)
Study: 31349916
Drug: 9-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-day course of dexamethasone (0.5 mg/kg/day followed by a rapid taper, n=29)
Study: 26472632
Drug: Computerized cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized cognitive remediation with concurrent meta-cognitive skills training (CCR + MST)
Study: 25348519
Drug: BC-3781 (pleuromutilin
Approvals — FDA: no, EMA: no, PMDA: no
Description: BC-3781 (pleuromutilin antimicrobial agent)
Study: 9288408
Drug: Buspirone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (10 mg)
Study: 12881823
Drug: Threshold inspiratory
Normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Threshold inspiratory muscle trainer, twice every other day, with 3 sets of 10 loaded inspirations (40%‐60% of patients' maximal inspiratory pressure [Pimax]) over a 10‐week period
Study: 8758084
Drug: Intramuscular artemether
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular artemether (3.2 mg/kg loading dose followed by 1.6 mg/kg daily)
Study: 8758084
Drug: Intravenous quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous quinine (20 mg/kg loading dose followed by 10 mg/kg every 8 h)
Study: 1881978
Drug: Capsulated aspartame
Normalized name: Aspartame
DrugBank: Aspartame (DB00168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsulated aspartame (400 mg)
Study: 1881978
Drug: Phenylalanine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylalanine (200 mg)
Study: 1881978
Drug: Aspartic acid
Normalized name: Aspartic Acid
DrugBank: Aspartic acid (DB00128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspartic acid (200 mg)
Study: 27009752
Drug: Western-style diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western-style diet (WD) supplemented with 2 g calcium carbonate/d for 4 weeks
Study: 27009752
Drug: Western-style diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western-style diet (WD) supplemented with 1,25(OH)2D3 (0.5 μg/d) for 4 weeks
Study: 27009752
Drug: Western-style diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western-style diet (WD) supplemented with 1,25(OH)2D3 (0.5 μg/d) and 2 g calcium carbonate/d for 4 weeks
Study: 25551175
Drug: Text message
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text message appointment reminders plus thrice-weekly supportive, informational, and motivational text messages
Study: 20660224
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g high‐MW oat β‐glucan/d (2,210,000 g/mol)
Study: 20660224
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g medium‐MW oat β‐glucan/d (850,000 g/mol)
Study: 20660224
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g medium‐MW oat β‐glucan/d (530,000 g/mol)
Study: 20660224
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g low‐MW oat β‐glucan/d (210,000 g/mol)
Study: 18709307
Drug: Cooling by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooling by frozen gel packs applied in the axilla for 5 min before treatment
Study: 12706612
Drug: Pulsed dye
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed dye laser treatment (585 nm, 5-6 J/cm², 3 treatments at monthly intervals)
Study: 2014075
Drug: Low-dose oxytocin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oxytocin regimen (increases at intervals of not less than 60 minutes)
Study: 6804311
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate 200 mg daily for 28 days
Study: 6804311
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate 400 mg daily for 28 days
Study: 6804311
Drug: Cimetidine 1
Normalized name: cimetidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 1 g daily for 28 days
Study: 26910613
Drug: Single-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose oral levofloxacin (500 mg)
Study: 19131212
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of wheat gluten hydrolysate (WGH)
Study: 19131212
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g of wheat gluten hydrolysate (WGH)
Study: 19131212
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g of wheat gluten hydrolysate (control)
Study: 17682989
Drug: Posaconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posaconazole (400 mg/day) for up to 6 months
Study: 28291508
Drug: Parecoxib sodium
Normalized name: parecoxib sodium
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib sodium 40 mg intravenous (group P, n = 30)
Study: 7481548
Drug: Interferon-alpha 2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha 2b treatment for 1 year
Study: 1929253
Drug: Cefprozil (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefprozil (500 mg once daily)
Study: 6644347
Drug: High-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose interferon treatment
Study: 6644347
Drug: Low-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose interferon treatment
Study: 27217449
Drug: Enzastaurin 500
Normalized name: Enzastaurin
DrugBank: Enzastaurin (DB06486)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzastaurin 500 mg daily for 3 years
Study: 19817718
Drug: Dexamethasone 9
Normalized name: DEXAMETHASONE 9% INTRAOCULAR SUSP KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 9 mg
Study: 7657740
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist [(imBzl)D‐His6, Pro9‐NEt]‐GnRH (D‐His) at doses of 0.01, 0.1, 1, and 10 micrograms/kg
Study: 28236981
Drug: Tecemotide (930μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tecemotide (930μg as lipopeptide) subcutaneously once weekly for 8 weeks, then every 6 weeks until disease progression or treatment withdrawal.
Study: 28236981
Drug: Placebo subcutaneously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneously once weekly for 8 weeks, then every 6 weeks until disease progression or treatment withdrawal.
Study: 21788267
Drug: Conventional neurological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional neurological therapy
Study: 21788267
Drug: Constraint induced
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint induced therapy
Study: 14510624
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment with negative inotropic agents (beta‐blockers, verapamil)
Study: 11052410
Drug: Pemoline treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemoline treatment (3 mg/kg/day, optimized dosing)
Study: 2455109
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 mg b.i.d.)
Study: 3239425
Drug: Carbachol, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbachol, 150 mg subcutaneously
Study: 3239425
Drug: Fundic distension
Normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fundic distension to a volume of 600 ml
Study: 30151941
Drug: Second course
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second course of intravenous immunoglobulins (IVIg) administered 1 week after the first course
Study: 30151941
Drug: Second course
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second course of intravenous immunoglobulins (IVIg)
Study: 23839050
Drug: Irinotecan at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan at dose level VI (240 mg/m²)
Study: 23839050
Drug: Irinotecan at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan at dose level VII (260 mg/m²)
Study: 23839050
Drug: Irinotecan (overall
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan (overall treatment)
Study: 21963063
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (Group A)
Study: 16482073
Drug: ALA-rich diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA-rich diet (6.8 g/day)
Study: 16482073
Drug: EPA/DHA-rich diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA/DHA-rich diet (1.05 g EPA/day + 0.55 g DHA/day)
Study: 2869950
Drug: Beta-adrenergic antagonists
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-adrenergic antagonists
Study: 11741055
Drug: Indomethacin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (25 mg three times a day for six weeks)
Study: 11741055
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (800 cGy within 72 hours post-surgery)
Study: 9438487
Drug: Loratadine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine (5 mg) plus pseudoephedrine (120 mg) (L/P)
Study: 1397240
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment protocol
Study: 8426204
Drug: Treatment protocol
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment protocol
Study: 3315542
Drug: Indomethacin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (150 mg daily by mouth)
Study: 3315542
Drug: Frusemide (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide (40 mg by mouth)
Study: 24136330
Drug: FF/VI 200/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF/VI 200/25 μg once-daily
Study: 24136330
Drug: FF 200
Normalized name: guaifen/pe/acetaminophen/caff 200 mg-10 mg-325 mg-32.5 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF 200 μg once-daily
Study: 24136330
Drug: FP 500
Normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP 500 μg twice-daily
Study: 20026784
Drug: Torcetrapib (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torcetrapib (60 mg)
Study: 12649629
Drug: Once-daily OROS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily OROS methylphenidate (OROS MPH)
Study: 11000370
Drug: Lifting of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifting of the abdominal wall (L)
Study: 2427840
Drug: Celiprolol 200
Normalized name: celiprolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol 200 mg daily for 2 weeks, then 400 mg daily for 2 weeks, and 600 mg daily for another 2 weeks for non-responders
Study: 18412271
Drug: Combined PCI
Normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined PCI and optimal medical therapy (OMT)
Study: 10385633
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg daily for 5 weeks
Study: 1997850
Drug: Prednisone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (40 to 0 mg per day for 8 days)
Study: 30321201
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy including desensitization manoeuvres of the central nervous system (n = 60)
Study: 26725717
Drug: Point prevalence
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Point prevalence of vaccine types HPV‐6,‐11,‐16, and ‐18
Study: 21992596
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day S‐(‐)equol for 12 weeks
Study: 15810623
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg bid
Study: 15810623
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg bid
Study: 15810623
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with antibiotic resistance
Study: 10203371
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (rhEPO) therapy
Study: 8652974
Drug: Hyperimmune bovine
Normalized name: Cryptosporidium hyperimmune bovine colostrum IgG
DrugBank: Cryptosporidium immune globulin (DB17785)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperimmune bovine colostrum (HBC) 100 ml three times a day for 3 consecutive days
Study: 2181565
Drug: nifedipine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifedipine (40 mg/day)
Study: 2181565
Drug: low salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: low salt diet (5 g of salt/day) and nifedipine
Study: 2181565
Drug: low salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: low salt diet (5 g of salt/day), nifedipine and a salt supplement (6 g/day)
Study: 2181565
Drug: unrestricted diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: unrestricted diet and nifedipine (40 mg/day)
Study: 2181565
Drug: unrestricted diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: unrestricted diet and medication
Study: 2181565
Drug: low salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: low salt diet (5 g of salt/day)
Study: 6379629
Drug: Cimetidine therapy
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine therapy
Study: 28418102
Drug: solifenacin 5
Normalized name: solifenacin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: solifenacin 5 mg + mirabegron 25 mg (combined S5 + M25 group)
Study: 28418102
Drug: solifenacin 5
Normalized name: solifenacin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: solifenacin 5 mg + mirabegron 50 mg (combined S5 + M50 group)
Study: 26663687
Drug: mirabegron 25
Normalized name: mirabegron 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: mirabegron 25 mg
Study: 21094194
Drug: Eating rate
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eating rate of foods (g/min)
Study: 26147635
Drug: Topical pimecrolimus
Normalized name: pimecrolimus Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical pimecrolimus 1% cream
Study: 18677657
Drug: Topical ketoconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ketoconazole 2% cream
Study: 17557047
Drug: Various endoscopic
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various endoscopic therapies for GERD
Study: 15286958
Drug: SS (supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: SS (supplements both before and after surgery)
Study: 15286958
Drug: CS (postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS (postoperative supplements only)
Study: 15286958
Drug: CC (no
Normalized name: INV-COVID-19 VACC (NOVAVAX) INJ 5ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC (no nutritional supplements)
Study: 15286958
Drug: SC (supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC (supplements only before surgery)
Study: 11150359
Drug: Dexamethasone (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.15 mg/kg/day for 3 days, followed by tapering over 7 days)
Study: 9744982
Drug: Oral Contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Contraceptive Pill (OCP)
Study: 7877205
Drug: Nadolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol (80 mg orally)
Study: 7877205
Drug: Isosorbide‐5‐mononitrate (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide‐5‐mononitrate (20 mg orally)
Study: 7877205
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with nadolol and isosorbide‐5‐mononitrate
Study: 7877205
Drug: Nadolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol (80 mg orally) followed by isosorbide‐5‐mononitrate
Study: 14594148
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral methadone (5 mg bd)
Study: 14594148
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg oral methadone (10 mg bd)
Study: 10885044
Drug: Free treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free treatment (90 days of substance abuse treatment)
Study: 10885044
Drug: Free treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free treatment
Study: 10885044
Drug: Paid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paid treatment
Study: 9374236
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea 3.6 g per day
Study: 9374236
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea 5.4 g per day
Study: 2989571
Drug: Ensure (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ensure (0 g/day soy fiber)
Study: 2989571
Drug: Enrich (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrich (30 g/day soy fiber)
Study: 2989571
Drug: Ensure with
Normalized name: Ensure with Fiber Vanilla
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ensure with 30 g/day soy fiber (diet c)
Study: 2989571
Drug: Ensure with
Normalized name: Ensure with Fiber Vanilla
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ensure with 60 g/day soy fiber (diet d)
Study: 24485347
Drug: Individual Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual Therapy (IP)
Study: 17996819
Drug: Continuous aortic
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous aortic flow augmentation using the Orqis Medical Cancion System (up to 1.5 L/min)
Study: 17996819
Drug: Continuous aortic
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous aortic flow augmentation
Study: 10356077
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid group (low in folate, approximately 210 micrograms of folate plus 250 micrograms of folic acid daily)
Study: 10356077
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (same low-folate diet as the folic acid group plus placebo tablet)
Study: 1673133
Drug: Intravenous metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metoprolol (15 mg)
Study: 7471621
Drug: Methapyrilene 20
Normalized name: methapyrilene
DrugBank: Methapyrilene (DB04819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methapyrilene 20 mg intravenously
Study: 7471621
Drug: Methapyrilene 50
Normalized name: methapyrilene
DrugBank: Methapyrilene (DB04819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methapyrilene 50 mg orally
Study: 7471621
Drug: Methapyrilene 25
Normalized name: methapyrilene 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methapyrilene 25 mg orally
Study: 24393328
Drug: Dexamethasone (16-16-12-12-8-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (16-16-12-12-8-4 mg/d)
Study: 23032160
Drug: Tetanus monovalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetanus monovalent vaccine (TMV; Vaccin Tétanique Pasteur® or Tetavax®)
Study: 23032160
Drug: Tetanus monovalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetanus monovalent vaccine (TMV)
Study: 17457706
Drug: ia 20
Normalized name: ammonia 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: ia 20 ml of 0.25 % bupivacaine at the end of the operation
Study: 17457706
Drug: ia 20
Normalized name: ammonia 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: ia 20 ml of 0.25 % bupivacaine and 100 mg of tramadol at the end of the operation
Study: 17457706
Drug: ia 100
Normalized name: Januvia 100mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ia 100 mg of tramadol diluted in 20 ml of saline solution 30 minutes before skin incision and 20 ml of 0.25% bupivacaine at the end of the operation
Study: 9615981
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 500 impulses of low‐energetic extracorporal shock‐wave therapy
Study: 9615981
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 100 impulses of low‐energetic extracorporal shock‐wave therapy
Study: 355810
Drug: Heparin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (100 international units per kilogram of body weight, subcutaneously every eight hours for two weeks)
Study: 31994374
Drug: Artichoke leaves
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artichoke leaves and ginger root extracts combination (320 mg) + simethicone (40 mg)
Study: 26401986
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D (50,000 IU every 5 days for 3 months)
Study: 20103833
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam 0.5 mg/kg (group M)
Study: 17543634
Drug: Tolvaptan (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan (30 mg/day)
Study: 8343002
Drug: Dual-lumen 10
Normalized name: Luden's Dual Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-lumen 10 French tunneled cuffed silastic central venous access catheter with a second proximal subcutaneous silver-impregnated cuff
Study: 27901218
Drug: Fluid solutions
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid solutions
Study: 22607269
Drug: Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of S1RA (5-500 mg, study 101; 500-800 mg, study 106)